EyePoint Pharmaceuticals, Inc. (EYPT) EPS Estimated At $-0.14; Concordia International Corphares (CXRX) Shorts Lowered By 5.96%

April 17, 2018 - By Winifred Garcia

Concordia International Corp. (NASDAQ:CXRX) Logo

Analysts expect EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) to report $-0.14 EPS on May, 3.They anticipate $0.01 EPS change or 6.67% from last quarter’s $-0.15 EPS. After having $-0.13 EPS previously, EyePoint Pharmaceuticals, Inc.’s analysts see 7.69% EPS growth. The stock increased 0.74% or $0.01 during the last trading session, reaching $1.36. About 56,049 shares traded. EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Concordia International Corphares (NASDAQ:CXRX) had a decrease of 5.96% in short interest. CXRX’s SI was 2.35M shares in April as released by FINRA. Its down 5.96% from 2.50 million shares previously. With 129,600 avg volume, 18 days are for Concordia International Corphares (NASDAQ:CXRX)’s short sellers to cover CXRX’s short positions. The SI to Concordia International Corphares’s float is 5.14%. The stock increased 1.49% or $0.0078 during the last trading session, reaching $0.5298. About 5,687 shares traded. Concordia International Corp. (NASDAQ:CXRX) has declined 69.63% since April 17, 2017 and is downtrending. It has underperformed by 81.18% the S&P500.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has market cap of $61.61 million. The firm has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU , which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. It currently has negative earnings. The Company’s lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

Among 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Concordia Healthcare Corp. had 20 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Sector Perform” rating given on Monday, September 19 by Scotia Capital. Canaccord Genuity maintained Concordia International Corp. (NASDAQ:CXRX) on Wednesday, August 9 with “Sell” rating. The company was downgraded on Wednesday, February 8 by TD Securities. The stock has “Underperformer” rating by IBC on Monday, August 15. The firm has “Outperform” rating given on Thursday, October 1 by RBC Capital Markets. The stock has “Buy” rating by Laurentian on Tuesday, March 29. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Neutral” rating given on Monday, August 15 by Goldman Sachs. The firm has “Neutral” rating by Goldman Sachs given on Monday, June 6. The stock of Concordia International Corp. (NASDAQ:CXRX) earned “Hold” rating by TD Securities on Thursday, August 4. The firm has “Sector Perform” rating given on Monday, November 30 by IBC.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $26.02 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: